Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) has a beta value of 0.59 and has seen 14,587,107 shares traded in the last trading session. The company, currently valued at $36.34 Million, closed the last trade at $2.07 per share which meant it lost -$0.3 on the day or -12.66% during that session. The SONN stock price is -682.61% off its 52-week high price of $16.2 and 12.56% above the 52-week low of $1.81. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1Million shares traded. The 3-month trading volume is 1.16 Million shares.
The consensus among analysts is that Sonnet BioTherapeutics Holdings Inc. (SONN) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 1 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $0.
Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) trade information
Despite being -12.66% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Monday, May 03 when the SONN stock price touched $2.73-2 or saw a rise of 24.18%. Year-to-date, Sonnet BioTherapeutics Holdings Inc. shares have moved -7.17%, while the 5-day performance has seen it change -0.48%. Over the past 30 days, the shares of Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) have changed -13.39%. Short interest in the company has seen 336Million shares shorted with days to cover at 289.66.
Wall Street analysts have a consensus price target for the stock at $8, which means that the shares’ value could jump 286.47% from current levels. The projected low price target is $8 while the price target rests at a high of $8. In that case, then, we find that the current price level is +286.47% off the targeted high while a plunge would see the stock lose 286.47% from current levels.
Sonnet BioTherapeutics Holdings Inc. (SONN) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +45.7% over the past 5 years. Earnings growth for 2021 is a modest +89.1%.
Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN)’s Major holders
Insiders own 7.61% of the company shares, while shares held by institutions stand at 2.67% with a share float percentage of 2.89%. Investors are also buoyed by the number of investors in a company, with Sonnet BioTherapeutics Holdings Inc. having a total of 17 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 246.56 Thousand shares worth more than $549.82 Thousand. As of December 30, 2020, Blackrock Inc. held 1.4% of shares outstanding.
The other major institutional holder is Vanguard Group Inc. (The), with the holding of over 135.96 Thousand shares as of December 30, 2020. The firm’s total holdings are worth over $303.2 Thousand and represent 0.77% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Micro Cap ETF. As of December 30, 2020, the former fund manager holds about 0.77% shares in the company for having 135963 shares of worth $303.2 Thousand while later fund manager owns 28.23 Thousand shares of worth $63.52 Thousand as of March 30, 2021, which makes it owner of about 0.16% of company’s outstanding stock.